SUPERFIBRONECTIN--A NEW ANTIMETASTATIC AGENT

Project Details

Description

DESCRIPTION: Tumorigenesis and metastasis depend upon a complex series
of events, and it is believed that cell attachment plays a critical role
in those processes. The applicants have developed a polymeric form of
the cell adhesion molecule fibronectin and have shown that this agent,
referred to as superfibronectin (sFN), inhibits cell attachment, as well
as cell migration in vitro. In vivo, sFN has anti-metastatic activity
towards several human tumors inoculated in immunodeficient mice.
Preliminary studies with ovarian carcinoma cell lines have shown that
sFN can restrict the growth and the peritoneal spread of injected tumor
cells. There have been no discernible toxic effects from the sFN
treatment. The applicants propose to: 1) test , as an initial step
toward designing clinical trials, the therapeutic effect of sFN in an
ovarian cancer animal model that mimics the human disease. 2) to assess
sFN toxicity focusing on the histological analysis of multiple organs
from animals treated with escalating doses of the polymer and 3) to
develop a light scattering test to standardize the production of the sFN
polymer. These studies are expected to provide the information needed
to proceed into experimental clinical trials after the phase II of this
grant.

PROPOSED COMMERCIAL APPLICATION: Not available.
StatusFinished
Effective start/end date5/1/984/30/00

Funding

  • National Cancer Institute
  • National Cancer Institute

ASJC

  • Cancer Research

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.